Polycythemia Vera (PV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Polycythemia vera (PV) is a myeloproliferative disorder that produces excessive red blood cells, white blood cells, and platelets, leading to elevated blood viscosity and various associated symptoms. The primary cause is the uncontrolled proliferation of red blood cells, often extending to white blood cells and platelets. While the exact origin of this abnormal stem cell expansion is debated, a somatic mutation known as JAK2-V617F in the JAK2 gene (9p24) is prevalent among most patients. However, less frequently, a somatic mutation in exon 12 of JAK2 can also be found. Symptoms of PV typically manifest insidiously and include headaches, dizziness, vertigo, tinnitus, visual disturbances, and itching after bathing. Patients may also exhibit a flushed appearance in their face, palms, nailbeds, mucosa, and conjunctiva. Complications associated with PV encompass arterial thrombosis (in cerebrovascular, myocardial, or peripheral regions), angina pectoris, intermittent claudications, venous thromboses (such as deep vein thrombosis and pulmonary embolism), splanchnic thrombosis (involving the portal vein and Budd-Chiari syndrome), and bleeding issues, including gum bleeding, ecchymoses, and gastrointestinal bleeding. Splenomegaly is also common in PV. In some cases, PV may progress to myelofibrosis, acute leukemia, or myelodysplastic syndrome, typically in the later stages of the disease. Diagnosing PV relies on several criteria, including a hematocrit (Hct) greater than 52% or hemoglobin (Hb) greater than 185 g/L in males, Hct greater than 48% or Hb greater than 165 g/L in females, an increased red blood cell mass (greater than 125% of the normal value), the presence of JAK2 mutations (V617F or exon 12), low levels of circulating erythropoietin (EPO), spontaneous colony formation by erythroid progenitor cells, and, in cases where JAK2 mutation is absent, evidence of a myeloproliferative disorder through bone marrow biopsy. Differential diagnosis involves ruling out other Ph1 negative myeloproliferative diseases, such as essential thrombocytosis and agnogenic myeloid metaplasia. PV is a chronic condition, and the survival rate of treated patients can be similar to the general population or slightly reduced, with a mortality rate 1.6 times higher than that of the general population. The FDA has approved ropeginterferon alfa-2b-njft (sold as BESREMi®) for the treatment of polycythemia vera (PV).
• The prevalence of PV in the United States is estimated to be between 44 and 57 cases per 100,000 people.

Thelansis’s “Polycythemia Vera (PV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polycythemia Vera (PV) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Polycythemia Vera (PV) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Polycythemia Vera (PV) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Polycythemia Vera (PV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Polycythemia Vera (PV), Polycythemia Vera (PV) market outlook, Polycythemia Vera (PV) competitive landscape, Polycythemia Vera (PV) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)